RB-3007
Names | |
---|---|
IUPAC name
Benzyl (2S)-2-[[(2S)-2-[[2-acetylsulfanylethoxy-[(R)-amino(phenyl)methyl]phosphoryl]methyl]-3-(4-phenylphenyl)propanoyl]amino]propanoate
| |
Other names
RB3007, LS-15768
| |
Identifiers | |
3D model (JSmol)
|
|
PubChem CID
|
|
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C37H41N2O6PS | |
Molar mass | 672.78 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
RB-3007 is an orally active analogue of RB-101. It acts as an enkephalinase inhibitor, which is used in scientific research.[1][2]
References
- ^ Thanawala, V.; Kadam, V.; Ghosh, R. (1 October 2008). "Enkephalinase Inhibitors: Potential Agents for the Management of Pain". Current Drug Targets. 9 (10): 887–894. doi:10.2174/138945008785909356. PMID 18855623.
- ^ Noble, Florence; Roques, Bernard P (17 January 2007). "Protection of endogenous enkephalin catabolism as natural approach to novel analgesic and antidepressant drugs". Expert Opinion on Therapeutic Targets. 11 (2): 145–159. doi:10.1517/14728222.11.2.145. PMID 17227231.